Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life population. (19th November 2019) - Van de Wyngaert, Zoe; Carpentier, Benjamin; Pascal, Laurent; Lionne‐Huyghe, Pauline; Leduc, Isabelle; Srour, Micha; Vasseur, Michele; Demarquette, Helene; Terriou, Louis; Herbaux, Charles; Manier, Salomon; Bossard, Jean‐Baptiste; et al.